How To Order

Getting started with ADSTILADRIN

Ferring Pharmaceuticals is committed to making access to ADSTILADRIN as seamless as possible. See below for a step-by-step guide to ordering ADSTILADRIN.

Step 1

Patient identification and submission of Patient Enrollment Form

  • Submit a completed Patient Enrollment Form: Once a patient is identified, submit the form by fax to 1-888-322-52331-888-322-5233 or online via You will receive a notification via email that your form has been successfully submitted
  • Ferring Access Support will conduct a benefits investigation.* Upon completion, Ferring Access Support will contact you via phone and/or fax with a benefits investigation summary, which will include details regarding the patient’s coverage:
    • Support options may be available for the patient
    • Results may include notifying your office of prior authorization requirements

Eligible, commercially insured patients may pay as little as $100
for each ADSTILADRIN prescription

ADSTILADRIN Copay Program Leave Behind Downloadable Guide
Download the ADSTILADRIN
Copay Program Leave Behind

Create an account, register and enroll patients, and submit claims on

Step 2

Account setup and ordering ADSTILADRIN

  • Please validate that your practice location has an active account set up with either Besse Medical or Optum Frontier Therapies
  • Account setup: If there is not an active account, please set up an account with Besse Medical by phone at 1-800-252-87591-800-252-8759 or by email at or with Optum Frontier Therapies by email at
    • Note: Account setup may take 3 to 5 business days provided that all information and documentation submitted are complete
  • Ordering ADSTILADRIN: Once benefits coverage is confirmed, you can proceed to order
    • To order through the specialty distributor, contact Besse Medical at 1-800-252-87591-800-252-8759 or Optum Frontier Therapies at 1-833-754-64571-833-754-6457
    • If ordering through the specialty pharmacy, Ferring Access Support will triage your prescription to Optum Frontier Therapies (1-855-768-97271-855-768-9727), and the patient and practice will be contacted by both Optum Frontier Therapies and Ferring Access Support
Step 3

Instillation of ADSTILADRIN

  • Schedule the instillation appointment with your patient—intravesical administration once every 3 months

For assistance, call 1-844-NADOnow (1-844-623-6669)
Monday to Friday, 9 AM to 6 PM ET

Ferring Access Support is here to help your clinic through the ADSTILADRIN ordering process

Hand and money icon



  • Dedicated case managers
  • Full benefits investigation
  • Billing to guidelines (compendia)
  • Prior authorization and appeal
Payment card icon

Financial services

Financial services

  • Copay program
  • Patient assistance program
  • Dedicated Field Reimbursement Managers
Patient representative icon

Patient services

Patient services

  • Coverage support
  • Appointment support
  • Adherence support



  • Product replacement
  • Shipment coordination
  • Instillation confirmation
*Only commercially insured patients will go through a benefits verification.
Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

Sign Up for Information

Sign up to receive information and updates on ADSTILADRIN

Your Information

Your Mailing Address

Interested in becoming a treatment site?*

*Required field.

Important Safety Information


ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.


CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.


  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?


ADSTILADRIN supply information

ADSTILADRIN is now fully available across the United States. We look forward to bringing ADSTILADRIN to patients and building on our mission at Ferring to help people live better lives.

To get ongoing updates about ADSTILADRIN, please sign up here.